144 related articles for article (PubMed ID: 32535115)
1. Chemical inhibition of β-glucocerebrosidase does not affect phagocytosis and early containment of Leishmania by murine macrophages.
Ribeiro H; Rocha MI; Castro H; Macedo MF
Exp Parasitol; 2020 Sep; 216():107939. PubMed ID: 32535115
[TBL] [Abstract][Full Text] [Related]
2. Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells.
Newburg DS; Shea TB; Yatziv S; Raghavan SS; McCluer RH
Exp Mol Pathol; 1988 Jun; 48(3):317-23. PubMed ID: 3371456
[TBL] [Abstract][Full Text] [Related]
3. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Kuo CL; Kallemeijn WW; Lelieveld LT; Mirzaian M; Zoutendijk I; Vardi A; Futerman AH; Meijer AH; Spaink HP; Overkleeft HS; Aerts JMFG; Artola M
FEBS J; 2019 Feb; 286(3):584-600. PubMed ID: 30600575
[TBL] [Abstract][Full Text] [Related]
4. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition.
Yatziv S; Newburg DS; Livni N; Barfi G; Kolodny EH
J Lab Clin Med; 1988 Apr; 111(4):416-20. PubMed ID: 3351378
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease.
van Weely S; Brandsma M; Strijland A; Tager JM; Aerts JM
Biochim Biophys Acta; 1993 Mar; 1181(1):55-62. PubMed ID: 8457606
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase deficiency and lysosomal storage of glucocerebroside induced in cultured macrophages.
Das PK; Murray GJ; Gal AE; Barranger JA
Exp Cell Res; 1987 Feb; 168(2):463-74. PubMed ID: 3803450
[TBL] [Abstract][Full Text] [Related]
7. Changes in macrophage morphology in a Gaucher disease model are dependent on CTP:phosphocholine cytidylyltransferase alpha.
Kacher Y; Golan A; Pewzner-Jung Y; Futerman AH
Blood Cells Mol Dis; 2007; 39(1):124-9. PubMed ID: 17482853
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease.
Berger J; Lecourt S; Vanneaux V; Rapatel C; Boisgard S; Caillaud C; Boiret-Dupré N; Chomienne C; Marolleau JP; Larghero J; Berger MG
Br J Haematol; 2010 Jul; 150(1):93-101. PubMed ID: 20507316
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
Mucci JM; Suqueli García F; de Francesco PN; Ceci R; Di Genaro S; Fossati CA; Delpino MV; Rozenfeld PA
Gene; 2013 Dec; 532(2):186-91. PubMed ID: 24076352
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease.
Rudensky B; Paz E; Altarescu G; Raveh D; Elstein D; Zimran A
Blood Cells Mol Dis; 2003; 30(1):97-9. PubMed ID: 12667991
[TBL] [Abstract][Full Text] [Related]
11. Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model.
Lamghari M; Barrias CC; Sá Miranda C; Barbosa MA
Blood Cells Mol Dis; 2005; 35(3):348-54. PubMed ID: 16125984
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
Campeau PM; Rafei M; Boivin MN; Sun Y; Grabowski GA; Galipeau J
Blood; 2009 Oct; 114(15):3181-90. PubMed ID: 19587377
[TBL] [Abstract][Full Text] [Related]
13. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.
Bondar C; Ormazabal M; Crivaro A; Ferreyra-Compagnucci M; Delpino MV; Rozenfeld PA; Mucci JM
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098793
[TBL] [Abstract][Full Text] [Related]
14. Measurement of lysosomal glucocerebrosidase activity in mouse liver using a fluorescence-activated cell sorter assay.
Chan KW; Waire J; Simons B; Karey K; Fung J; Copeland D; Andrews L
Anal Biochem; 2004 Nov; 334(2):227-33. PubMed ID: 15494128
[TBL] [Abstract][Full Text] [Related]
15. Studies on the turnover of glucocerebrosidase in cultured rat peritoneal macrophages and normal human fibroblasts.
Das PK; Murray GJ; Barranger JA
Eur J Biochem; 1986 Jan; 154(2):445-50. PubMed ID: 3943537
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
17. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
18. A flow cytometric assay for lysosomal glucocerebrosidase.
van Es HH; Veldwijk M; Havenga M; Valerio D
Anal Biochem; 1997 May; 247(2):268-71. PubMed ID: 9177687
[TBL] [Abstract][Full Text] [Related]
19. Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.
Grabowski GA; Dinur T; Osiecki KM; Kruse JR; Legler G; Gatt S
Am J Hum Genet; 1985 May; 37(3):499-510. PubMed ID: 4003396
[TBL] [Abstract][Full Text] [Related]
20. N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.
Adams BT; Niccoli S; Chowdhury MA; Esarik AN; Lees SJ; Rempel BP; Phenix CP
Chem Commun (Camb); 2015 Jul; 51(57):11390-3. PubMed ID: 26085065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
